Grupo 1 Type of group

4 trials

Sponsors

GLAXOSMITHKLINE PERU S.A.,, BRISTOL MYERS SQUIBB PERU S.A.,, NOVARTIS BIOSCIENSES PERU S.A.,, BRISTOL MYERS SQUIBB COMPANY,

Unknown Phase

PHASE III STUDY ON THE SECURITY AND ANTIVIRAL ACTIVITY OF ENTECAVIR VS. LAMIVUDINE IN ADULTS WITH INFECTION WITH CHRONIC HEPATITIS B AND NEGATIVES FOR ANTIGENE E OF HEPATITIS B

Active, not recruitingPER-044-01

BRISTOL MYERS SQUIBB PERU S.A.,

Updated: 2023-09-04

8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension

Active, not recruitingPER-068-06

NOVARTIS BIOSCIENSES PERU S.A.,

Start: 2006-12-18Target: 50Updated: 2023-09-04

A 12-Week Study To Assess The Safety Of Fluticasone Propionate/Salmeterol 100/50 Hydrofluoroalkane (HFA) Versus Fluticasone Propionate 100 HFA In Children With Asthma

Active, not recruitingPER-017-07

GLAXOSMITHKLINE PERU S.A.,

Target: 27Updated: 2023-09-04

An Open-Label, Randomized, Multicenter Phase III Trial of Dasatinib (SPRYCEL ) vs. Standard Dose Imatinib (400 mg) in the Treatment of Subjects with Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive Chronic Myeloid Leukemia.

Active, not recruitingPER-071-07

BRISTOL MYERS SQUIBB COMPANY,

Target: 15Updated: 2023-09-04